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Recent studies suggest that monocytes are the dominant effectors
by which rituximab induces cell death in B-cell lymphoma. Because
macrophage colony-stimulating factor (M-CSF) can enhance the
cytotoxicity of monocytes, the authors examined whether this
growth factor can enhance their ability to kill lymphoma cells in
vitro. Monocytes derived from a healthy volunteer were cultured
for 48 h in the presence or absence of M-CSF. Monocytes stimul
ated with M-CSF were significantly more cytotoxic to Daudi B-cell
lymphomas than unstimulated monocytes. Flow cytometry revealed
that M-CSF increased monocyte expression of Fcγ receptors III and I
by 1.6- and 1.5-fold, whereas the expression of Fcγ receptor II
remained unchanged. These results suggest that pretreatment with
M-CSF can improve the therapeutic efficacy of rituximab against
intractable CD20+ lymphoma. (Cancer Sci 2007; 98: 1368–1372)
R ituximab, a chimeric anti-CD20 IgG1 monoclonal antibody,has dramatically improved the treatment of both follicular
and aggressive CD20+ B-cell non-Hodgkin lymphomas.(1–5)
However, the advantage of rituximab is not whole. A substantial
number of patients suffer from relapse after rituximab containing
chemotherapy or refractoriness to it.(1–5) Approximately half of
patients with relapsed or refractory non-Hodgkin lymphoma do
not exhibit a durable clinical response to rituximab, despite
continued expression of CD20 by lymphoma cells.(1,3,6)
Although the means by which rituximab inhibits the growth
of lymphoma is not fully understood, accumulating evidence
indicates that it is mostly mediated by antibody-dependent
cellular cytotoxicity (ADCC) rather than induction of apoptosis
and complement-dependent cytotoxicity.(7–12) In addition, studies
in a mouse model of rituximab immunotherapy revealed that B
cells depletion via ADCC is mostly mediated by monocytes
rather than T or natural killer cells.(13)
Macrophage colony-stimulating factor (M-CSF), also known
as colony-stimulating factor 1, promotes the differentiation of
progenitor cells into mature monocytes and macrophages and
prolongs macrophage and monocyte survival.(14–20) Previous
studies have demonstrated that M-CSF activates monocytes,
leading to greater ADCC against target cells, including human
lymphoma and leukemic cell lines.(18,19) In the present study, the
authors investigated whether M-CSF can enhance the ability of
monocytes to kill CD20+ lymphoma cells via a rituximab-
dependent mechanism.
Materials and Methods
Cell lines. Daudi Burkitt’s lymphoma cells, Molt-4 acute lymphoid
leukemia cells, and THP-1 acute monocytic leukemia cells
were purchased from the Riken Cell Bank (Tsukuba City,
Japan). Daudi cells express CD20 on their surface, whereas
Molt-4 cells lack cell surface CD20. Cell lines were cultured in
complete medium, which contained Roswell Park Memorial
Institute (RPMI) 1640 (Gibco Laboratories, Grand Island, NY,
USA), 10% heat-inactivated fetal bovine serum (Gibco Laboratories),
2 mmol/L l-glutamine (Gibco Laboratories), and penicillin-
streptomycin (Gibco Laboratories). Cells in the late logarithmic
phase of growth were passaged regularly every 4–5 days prior to
cytotoxicity assays. The cell lines used for experiments were
≥90% viable according to Trypan blue exclusion.
Monoclonal antibodies and cytokines. The chimeric anti-CD20
monoclonal antibody rituximab was purchased from Roche
Pharmaceuticals (Basel, Switzerland). Mouse fluorochrome-
conjugated isotype control antibodies, phycoerythrin-conjugated
anti-CD32 and anti-CD14, and fluorescein isothiocyanate-
conjugated anti-CD64 and anti-CD16 antibodies were purchased
from BD Biosciences (San Jose, CA, USA). Anti-CD16 blocking
antibody was purchased from Abcam (Cambridge, UK), anti-CD32
blocking antibody from StemCell (Vancouver, British Columbia,
Canada), and unconjugated anti-CD64 antibody from BD
Biosciences (San Jose, CA, USA). Recombinant human M-CSF
was purchased from Peprotech (London, UK).
Flow cytometry. Flow cytometric phenotyping of target and
effector cells was carried out on a FACScan flow cytometer
(Becton Dickinson, Mountain View, CA, USA). The levels of
Fcγ receptor (FcγR) I, II, and III on monocytes were quantified
from the median fluorescence intensities obtained using monoclonal
antibodies against CD64, CD32, and CD16, respectively. Two-
parameter dot plots were generated using CellQuest software
(Becton Dickinson Immunocytometry Systems, San Jose, CA,
USA), and acquired cytometric data were analyzed with
FlowJo software (Tree Star Inc., Ashland, OR, USA). The mean
fluorescence intensity of each marker was compared between
freshly isolated monocytes and monocytes that had been
cultured for 48 h with or without M-CSF.
Isolation of monocytes. Peripheral blood mononuclear cells
from eight healthy volunteers were isolated using the Ficoll-
Hypaque gradient (Pharmacia Biotech, Uppsala, Sweden) and
used for negative selection of blood monocytes by depleting
T cells, B cells, natural killer cells, and granulocytes using a
StemSep Monocyte Enrichment Kit (StemCell Technologies,
Vancouver, British Columbia, Canada) according to the manu-
facturer’s instructions. The purified cell fraction contained more
than 90% monocytes as determined by flow cytometry and
microscopic examination of the cell morphology.
Stimulation of monocytes with M-CSF. Isolated monocytes were
cultured for 48 h in the presence or absence of 66 ng/mL M-
CSF at 37°C in 5% CO2. The concentration of M-CSF for optimal
stimulation of the monocytes was determined as described
previously.(19)
Cytotoxicity assay. Cytotoxicity was measured using flow
cytometry with a LIVE/DEAD Viability/Cytotoxicity Assay Kit
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(Molecular Probes, Eugene, OR, USA) as described previously.(21)
In this assay, living cells are stained with calcein-AM
(green fluorescence), and dead cells are stained with ethidium
homodimer-1 (red fluorescence). Target cells were cultured with
rituximab (5 µg/mL) or human IgG1 (control) for 30 min at
room temperature. Effector cells were adjusted to 1 × 106/mL.
Target and effector cells were cocultured in sterile polystyrene
round bottom tubes (Becton Dickinson Labware, Franklin Lakes,
NJ, USA) in complete medium at various effector-to-target
ratios for 4 h at 37°C in 5% CO2. At the end of incubation, cells
were stained with EH-1 (100 nM). Next, 104 cells per sample
were examined using FACScan flow cytometry without gating.
Acquired cytometric data were analyzed with FlowJo software
(Tree Star Inc.), and cytotoxicity was calculated according to the
manufacturer’s instructions. Cytotoxicity assays were repeated
at least three times for each sample.
Statistical analysis. The data were expressed as means ± SD. Paired
t-tests were performed to determine the statistical significance
of differences between two groups. Values of P < 0.05 were
considered to indicate a statistically significant difference.
Results
M-CSF enhances monocyte-mediated rituximab-induced death of
CD20-positive lymphoma cells. In initial experiments, monocytes
were incubated for 48 h in the presence or absence of M-CSF
and then the killing of rituximab-coated lymphoma cells was
measured (Figs 1,2). At an effector-to-target ratio of 5:1, monocytes
treated with M-CSF were significantly more cytotoxic to Daudi
CD20-positive lymphoma cells than untreated monocytes. In
contrast, neither M-CSF-treated nor -untreated cultured monocytes
induced the lysis of rituximab-coated, CD20-negative Molt-4
cells (Fig. 3). Also, regardless of whether the monocytes were
treated with M-CSF, they did not cause substantial lysis of
Daudi cells coated with isotype-matched control IgG (Fig. 2).
Furthermore, in the absence of effector cells, rituximab alone
did not exhibit substantial cytotoxicity against Daudi (Fig. 2) or
Molt-4 cells (Fig. 3), indicating that the lysis of Daudi cells was
due to rituximab-dependent, monocyte-mediated ADCC.
Analysis of FcγR on monocytes. The effect of M-CSF on the
expression of FcγRI (CD64), FcγRII (CD32), and FcγR (CD16)
on CD14+ monocytes was examined next using flow cytometry.
As shown in Fig. 4, M-CSF caused a statistically significant
increase in the level of FcγRI (1.6-fold; P = 0.00031) and
FcγRIII (1.5-fold; P = 0.039) on monocytes. The expression of
FcγRII, however, was not affected by stimulation with M-CSF
(P = 0.25).
Blocking of cytotoxicity by anti-FcγR antibodies. Acute monocytic
leukemia cell line THP-1 cells can induce ADCC using FcγR on
their cell surface, which is a good model with which to test the
cytotoxic mechanisms of monocytes.(22)
Stimulation of THP-1 cells with M-CSF increased their
cytotoxicity against Daudi cells coated with rituximab by 20%,
and amplified their expression of FcγR I and III but not FcγR II
Fig. 1. Specific lysis of CD20-positive (Daudi) and CD20-negative
(Molt-4) target cells at different effector-to-target (E : T) ratios in the
presence of rituximab (5 µg/mL). Monocytes of healthy volunteers
(n = 8) were isolated by negative selection and cultured in the presence
or absence of macrophage colony-stimulating factor (M-CSF; 66 ng/mL)
for 48 h. M-CSF-treated monocytes displayed greater cytotoxicity
toward Daudi cells than M-CSF-untreated monocytes. Also, specific lysis
of Daudi cells by M-CSF-treated monocytes in the presence of rituximab
increased as the E : T ratio was increased. In contrast, the lysis of Molt-
4 cells was not increased as the E : T ratio was increased. The results are
representative of three independent experiments.
Fig. 2. Effect of macrophage colony-stimulating factor (M-CSF) on the
lysis of CD20-positive cells (Daudi) by monocytes at an effector-to-
target (E : T) ratio of 5:1 in the presence of rituximab (5 µg/mL).
Monocytes were derived from healthy volunteers (n = 8) and cultured
in the presence or absence of M-CSF (66 ng/mL) for 48 h. Specific lysis
was significantly higher in M-CSF-treated monocytes than in monocytes
that were not treated with M-CSF (mean ± SD, 46.2% ± 28.6% vs
34.7% ± 31.9%, respectively [n = 8]; P = 0.0015). Specific lysis by
rituximab (5 µg/mL) in the absence of effector cells was 13.1% ± 8.2%.
Specific lysis by monocytes in the absence of rituximab was 12.6% ± 8.1%
for M-CSF-treated monocytes and 11.3% ± 7.0% for M-CSF-untreated
monocytes. In the absence of rituximab, monocytes did not cause
substantial cells lysis irrespective of M-CSF stimulation compared to
Daudi cells’ autolysis.
Fig. 3. Macrophage colony-stimulating factor (M-CSF)-stimulated
monocytes do not cause rituximab-mediated cell death of CD20-
negative cells (Molt-4). Monocytes from eight healthy volunteers were
used for cytotoxicity assay. Specific lysis of target cells was 3.94% by M-
CSF-stimulated monocytes in the presence of rituximab (5 µg/mL),
3.29% by M-CSF-untreated monocytes in the presence of rituximab,
and 2.56% by rituximab in the absence of monocytes. The results are
representative of two independent experiments.
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(Fig. 5a), as seen in freshly isolated monocytes. Blocking of FcγRI
(CD64), FcγRII (CD32), and FcγRIII (CD16) inhibited the
specific lysis of rituximab-coated Daudi cells by M-CSF treated
THP-1 (Fig. 5b), suggesting that the FcγR expression on
effector cells may be pivotal for rituximab-mediated ADCC
by monocytes.
Discussion
In the present study, it was demonstrated that M-CSF enhanced
monocyte-induced, rituximab-mediated ADCC of CD20+ lymphoma
cells. Although the mechanism by which M-CSF enhances
monocyte cytotoxicity remains unknown, the present results
suggest that this may partly be due to an increase in monocytes
expression of FcγRI and FcγRIII. This hypothesis is supported
by a previous study showing that rituximab-mediated depletion
of B cells depends on monocytes expression of FcγRI and
FcγRIII.(13) The importance of FcγR is also supported by the
finding that follicular lymphoma patients with the FcγRIIIa
158 V allotype exhibit a higher affinity for human IgG1 and
show better clinical responses to rituximab than those with the
FcγRIIIa 158F allotype, who exhibit a lower affinity for human
IgG1.(11,23) Monocyte enhancement of rituximab-mediated ADCC
by M-CSF may also be due to prolonged activation of signal
transduction pathways that promote cell survival, including the
mitogen-activated protein kinase and phosphatidylinositol 3-
kinase/Akt pathways,(15,16,19) although additional studies are needed
to examine this possibility in detail.
Colony-stimulating factor 1op mice, which are M-CSF-deficient
and lack bone marrow macrophages and blood monocytes,(24)
exhibit slow clearance of circulating B cells after treatment with
CD20 monoclonal antibody and do not clear all of the mature
spleen B cells.(13) In contrast, in mice lacking functional T cells
and in perforin-deficient mice, which have defective natural
killer cell function, more than 95% of blood and spleen B cells
are eliminated after treatment with CD20 monoclonal antibody.
Furthermore, classical or alternative pathway C activation does
not contribute to B-cell depletion in the M-CSF-deficient mouse
model. Based on these findings, it has been concluded that
monocytes, as well as the innate monocyte network, are the major
effectors mediating depletion of CD20+ B cells in vivo. This
may also be supported by the authors’ findings that monocyte
Fig. 4. Effect of M-CSF on the expression of Fcγ receptor (FcγR) by
monocytes. The levels of FcγR on the surface of monocytes from eight
healthy volunteers were measured using flow cytometry after a 48 h
treatment in the presence or absence of macrophage colony-
stimulating factor (M-CSF). The median fluorescence intensities of FcγR
on monocytes from the same volunteers were compared using a paired
t-test. (a) The expression of FcγRI on monocytes was significantly
enhanced by treatment with M-CSF (60% increase; P = 0.00031). (b) The
expression of FcγRIII on monocytes was significantly enhanced by
treatment with M-CSF (50% increase; P = 0.039). (c) The expression of
FcγRII was not significantly changed by treatment with M-CSF.
Fig. 5. (a) The expression of CD64 and CD16 on THP-1 were
significantly enhanced by treatment with macrophage colony-
stimulating factor (M-CSF). (b) Blocking of cytotoxicity mediated by
THP-1 against Daudi cells. A total 2.5 × 105 THP-1 cells treated with M-
CSF were incubated with 5 × 104 Daudi cells in the presence of 5 µg/mL
rituximab in medium containing isotype control IgG (control) or
indicated purified monoclonal blocking antibodies (40 µg/mL): anti-
CD16, CD32, CD64. The percentage inhibition was calculated using the
mean percentage of specific lysis determined from triplicate cultures
after 4 h of incubation.
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activation by M-CSF significantly improves the killing of
CD20+ malignant cells via rituximab-mediated ADCC. Although
the Daudi Burkitt’s lymphoma cell line that was used as in vitro
model of B-cell lymphoma is not a major target of rituximab
therapy in the clinical setting, several reports(25,26) have shown
Burkitt’s lymphoma cell lines are acceptable as targets to evaluate
rituximab-mediated ADCC.
Several studies have examined how cytokines that augment
effector cell numbers and function and/or induce antigen expression
on target cells affect ADCC in the context of rituximab ther-
apy.(25,27–30) Interferon-α,(31) interleukin (IL)-2,(28) and IL-12(32)
have been effectively combined with rituximab in small-group
trials; however, the substantial toxicity of such proinflammatory
cytokines might limit their overall utility in clinical settings.
Granulocyte colony-stimulating factor (G-CSF), which has a
relatively low toxicity profile, and granulocyte-monocyte colony-
stimulating factor (GM-CSF) have been reported to enhance the
in vitro efficacy of rituximab by enhancing the ADCC of neu-
trophils.(25) In addition, in a severe combined immunodeficiency
mouse lymphoma model, the concurrent administration of
G-CSF augments the biological activity of rituximab, probably by
increasing neutrophil counts.(33) Such a boost in the efficacy of
rituximab does not occur with GM-CSF, although it also increased
the neutrophil count. In preliminary clinical trials for relapsed or
refractory B-cell non-Hodgkin lymphoma, the administration
of G-CSF(30) and GM-CSF(34) appeared to enhance the effect of
rituximab. Similar clinical trials using M-CSF in place of G-CSF
and GM-CSF are warranted because of the lower toxicity of M-
CSF.(35) Because administration of M-CSF causes a 10-fold increase
in the numbers of blood monocytes and an increase in the numbers
of macrophages in the liver, spleen, and peritoneal cavity,(20)
M-CSF priming could be a reasonable approach for improving
the therapeutic efficacy of rituximab against intractable CD20+
lymphoma, particularly in the late stages of the disease.
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